What a brutal six months it’s been for 10x Genomics. The stock has dropped 52.1% and now trades at $10.59, rattling many ...

In this article, we are going to take a look at where 10x Genomics, Inc. (NASDAQ:TXG) stands against the other genomics stocks. Genomics is the study of genes and how they function. Many rapidly ...

Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 8.5% in the pre-market session after the company reported disappointing fourth-quarter results: its EPS missed significantly, and its full ...

10x Genomics (NASDAQ:TXG – Free Report) had its price objective trimmed by JPMorgan Chase & Co. from $14.00 to $12.00 in a research note issued to investors on Thursday morning,Benzinga reports.

10x Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by Morgan Stanley from $28.00 to $26.00 in a research report issued to clients and investors on Friday,Benzinga reports.

Citi lowered the firm’s price target on 10x Genomics (TXG) to $15 from $20 and keeps a Buy rating on the shares. The firm updated models in the ...

Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The company’s shares closed yesterday at $11.94.

In trading on Monday, shares of 10x Genomics Inc (Symbol: TXG) entered into oversold territory, hitting an RSI reading of 27.9, after changing hands as low as $11.8955 per share. By comparison ...

The market expects 10x Genomics (TXG) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...